Introduction {#sec1-1}
============

Disorders of unknown etiology have historically been linked to psychosomatic causes. In gastroenterology, one example is ulcerative colitis (UC) before the advent of flexible endoscopy. Historically, UC was linked to Freudian anal regression caused by a difficult dilemma facing the patient \[[@ref1]\]. The psychosomatic hypothesis in UC remained prominent for many decades. Evaluations were conducted to assess the psychosomatic theory \[[@ref2]\] almost concurrently with classic evaluations of immunomodulating agents \[[@ref3]\]. As recent as twenty years ago, a well-conducted systematic review failed to find an association between psychological factors and UC \[[@ref4]\]. As UC was slowly legitimized as an organic disease process, the role of stress and psychological contributions took a back seat to theories of immune dysfunction and potential environmental factors \[[@ref5]\].

It is well-known that irritable bowel syndrome (IBS) and psychological illnesses are often co-morbid conditions \[[@ref6],[@ref7]\]. A prior systematic review also revealed that IBS is common in patients with chronic fatigue syndrome, pelvic pain, temporomandibular joint disorder which are all theorized to have some psychological component in their manifestation \[[@ref8]\]. Despite these findings, a true prospective study has yet to prove that IBS is actually caused by, rather than merely associated with, psychological stressors. Emerging data are beginning to characterize potential pathophysiologic mechanisms of IBS such as post-infectious IBS or altered gut microbiota which argue against a mainly psychological root cause \[[@ref9],[@ref10]\]. Moreover, the role of microinflammation in the bowel wall in IBS is becoming clear which may explain overlapping IBS-like symptoms in IBD patients \[[@ref11]\].

The effects of illness and disability on the psychological wellbeing of humans are well documented in the literature \[[@ref12]-[@ref15]\]. Psychological illnesses can worsen disease through factors separate from the pathophysiology of the medical condition, such as non-adherence to therapy and follow up \[[@ref16],[@ref17]\] as well as lifestyle choices known to worsen the underlying condition \[[@ref18],[@ref19]\]. Regardless of cause, the resulting combination of co-morbid medical and psychological conditions leads to poor outcomes \[[@ref20],[@ref21]\]. Co-morbid psychological illness may potentiate or predict the presence of a medical disorder but does not necessarily have to cause the medical condition \[[@ref22]\].

We postulated that the association between IBS and psychological factors might be attributed to the general psychological stress of suffering from chronic and often debilitating disease or a derangement of the gut-microbiome-brain axis involving dysbiosis of neurocognitive function. Based on this, it would be reasonable to consider a similar association with psychological disorders in other disease literature as well. Therefore, we aimed to identify the severity of depression and anxiety symptoms measured with scoring symptoms using validated patient questionnaires of IBS patients relative to healthy controls, and to compare these data with similar data in the UC literature on the basis of both illnesses being traditionally classified as colonic diseases.

Methods {#sec1-2}
=======

Study design {#sec2-1}
------------

We conducted a PubMed literature search (7 May 2013) to identify relevant case-control studies evaluating co-morbid psychological factors in two populations of patients with two gastrointestinal (GI) illnesses typically classified as colonic diseases: patients with IBS or UC compared to a healthy population. Search terms are shown in the *supplement*. Due to our pooled endpoint, IBS studies were limited to those evaluating Rome criteria to increase the homogeneity of IBS patient populations. Inclusion criteria were then applied ([Table 1](#T1){ref-type="table"}) to identify relevant studies for this analysis. Data were extracted by ES and reviewed by ES and MP.

###### 

Eligibility criteria
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Extracted data included methodology of recruiting and enrolling patients, eligibility criteria for case or control groups, sex distribution of enrolled patients, and criteria for determining presence or severity of depression and anxiety.

Endpoints and statistical analysis {#sec2-2}
----------------------------------

Our primary endpoint was the percentage of patients identified as having co-morbid depression or anxiety with the respective GI illness, relative to a healthy control population, based on a threshold score using a validated patient questionnaire. As a secondary endpoint, we evaluated the severity of depression and anxiety symptoms in patients with the respective GI illness relative to healthy controls based on reported validated scoring systems. Scoring methods such as the Hospital Anxiety and Depression Index (HADS) report the sum of patient-reported symptoms as well as symptom severity with a validated cut-off threshold to represent major depressive disorder or anxiety disorder. Study results were arithmetically summed wherever matching criteria were identified which evaluated the presence or severity of depression and anxiety.

Results {#sec1-3}
=======

We identified seven eligible IBS studies and three eligible studies of UC ([Fig. 1](#F1){ref-type="fig"}). The severity of anxiety and depression symptoms was measured using discrete numerical scales which are well described \[[@ref23]-[@ref27]\]. The percentage of females in either case or control cohorts ranged from 42% to 81%. The full characteristics of eligible studies were variable ([Table 2](#T2){ref-type="table"}).

![Flowchart of literature search](AnnGastroenterol-27-224-g002){#F1}

###### 

Summary of studies
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Prevalence of anxiety and depression in IBS and UC {#sec2-3}
--------------------------------------------------

Two studies of IBS reported the prevalence of depression and anxiety based on HADS \[[@ref28]\] or the Beck Anxiety and Depression Inventories (BAI/BDI)\[[@ref29]\]. In Hartono *et al*, the excess prevalence of depression and anxiety was 38.7% and 6.5%, respectively, in IBS patients relative to healthy patients (of which 6.5% and 14.5% reported scores consistent with depression and anxiety), based on diagnostic criteria of a HADS rating greater than eight \[[@ref28]\]. In Uz *et al*, the excess prevalence of depression or anxiety relative to healthy controls was 34% and 2%, with 4% and 8% of the healthy population reporting scores consistent with depression and anxiety \[[@ref29]\]. Pooled data are reported in [Fig. 2](#F2){ref-type="fig"} and [Table 3](#T3){ref-type="table"}.

One study of UC evaluated the prevalence of depression and anxiety relative to healthy controls \[[@ref30]\]. The excess prevalence of anxiety in UC patients relative to healthy controls was 41.7% (with a 22.2% baseline prevalence in healthy patients) based on a State-Trait Anxiety Inventory (STAI) score greater than 40. Excess depression of 38.9%, with a baseline prevalence of 11.1% in the healthy population, was evaluated with a Zung Depression Scale (ZDS) score greater than 49.

Severity of anxiety and depressive symptoms in IBS and UC {#sec2-4}
---------------------------------------------------------

Three studies reported severity of symptoms supportive of anxiety based on an average HADS rating \[[@ref31]-[@ref33]\]. The pooled average anxiety-specific HADS rating derived from these studies was 8.1 among IBS patients and 3.8 among healthy controls. In comparison, the average anxiety-specific HADS rating in one UC study was 8.5 in UC patients and 3.2 in healthy controls \[[@ref34]\]. In addition, anxiety ratings based on STAI were higher among UC patients (51.9) than healthy controls (41.8)\[[@ref35]\].

Average ratings of depressive symptoms were reported in three IBS trials \[[@ref31]-[@ref33]\]. The pooled average depression-specific HADS rating was 5.4 among IBS patients and 2.4 among healthy controls in two studies \[[@ref31],[@ref32]\]. Another study reported an average short-form BDI rating of 5.9 in IBS patients and 1.7 in healthy controls \[[@ref33]\]. Two additional studies reported significant higher anxiety and depression ratings in IBS patients than controls though mean scores were not reported \[[@ref36],[@ref37]\]. One UC study reported an average HADS rating of 4.1 among UC patients and 1.7 among healthy controls \[[@ref34]\].

For all utilized depression and anxiety rating scales, higher ratings reflected more prominent and prevalent symptoms suggestive of depression or anxiety. Data are reported in [Fig. 2](#F2){ref-type="fig"} and [Table 3](#T3){ref-type="table"}.

![Portion of psychological condition attributable to gastrointestinal disease (in excess of control group). (A) Prevalence of concomitant psychological illness (in excess of healthy control) for irritable bowel syndrome (IBS) and ulcerative colitis (UC). (B) Scores for depression and anxiety are reported for both IBS and UC (in excess of scores for healthy controls). There were no studies reporting average STAI scores for IBS and no studies reporting average BDI scores for UC](AnnGastroenterol-27-224-g004){#F2}
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Pooled results of case-control studies evaluating psychological illness in irritable bowel syndrome or ulcerative colitis
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Discussion {#sec1-4}
==========

In this paper, published studies demonstrate that the prevalence of anxiety and depression is higher in both UC and IBS patients as compared to healthy controls. In addition, there is an increase in the severity of anxiety- and depression-related symptoms among UC and IBS patients relative to healthy controls.

The traditional brain-gut axis hypothesis suggests that disordered autonomic and neural gut regulation as well as dysregulated visceral feedback lead to IBS \[[@ref38],[@ref39]\]. Visceral hyperalgesia is a common finding in IBS subjects \[[@ref40]\], and brain imaging \[[@ref41]\] suggests altered responses in IBS compared to controls. However, these studies do not explain the exact cause of visceral hypersensitivity or show a causal association of IBS with stress, anxiety, or psychological trauma. It is therefore still unclear if central processing or peripheral signaling to the brain is dysfunctional. Alternatively, conditioning (or hypervigilance) to illness-related symptoms could alter the pathways of pain as a matter of coping \[[@ref42]\].

The greatest pitfall in the study of the relationship between IBS and psychological disorders is in the selection of control subjects. Healthy controls are "healthy". By definition, they should have a near-zero illness score for somatic or psychological illness. With this comparison, any disease (from congestive heart failure to eczema) would have some degree of personal anxiety due to physical limitations or appearance. By design, IBS is therefore associated with anxiety and depression. One argument could be that psychological disorders are associated with all illness and are therefore always important. However, one must ask whether the focus is to treat the underlying disease which thus alleviates anxiety and depression, or to treat the depression and anxiety while the medical illness remains \[[@ref14]\]. Another argument is that the presence of a psychological disorder might adversely affect subjective patient-reported outcomes as is controversially reported in other disease literature \[[@ref43]\]. A number of successful therapies have been derived from this hypothesis. Previous meta-analyses support antidepressants and cognitive behavioral therapy in treating IBS based on subjective endpoints \[[@ref44]\]. Cognitive behavioral therapy is based on learning effective strategies of coping with dysfunctional thoughts derived from physical symptoms \[[@ref45]\]. The result is an improvement in the same patient-reported outcomes measured in pharmacologic studies without the need for a physical improvement in the objective disease. Similarly, in UC, the recent INSPIRE study found that stress management might improve quality of life though it did not alter the objectively-defined disease course \[[@ref46]\].

In this study, we found associations with psychological disorders in both IBS and UC case-control literature. As this finding was not limited to IBS literature alone, it would be reasonable to consider our results in the context of the severe disability and impaired quality-of-life associated with both illnesses \[[@ref47],[@ref48]\] as is seen in other chronic illnesses such as HIV, cancer, and ischemic heart disease \[[@ref49]\]. This is in contrast to prior conclusions that these associative data might support a psychological mechanism of IBS development \[[@ref8]\], as it is clear that case-control studies cannot prove causality on their own. Despite this, the role of psychological health in GI disease is not entirely clear. In one prospective study of 17 patients with active UC, hypnotic therapy was associated with reductions in systemic and mucosal inflammatory response two hours after the therapeutic session ended \[[@ref50]\].

Beyond associative studies, the psychosomatic theory in IBS is supported by retrospective cohort studies which revealed preceding psychological illness in clinical interviews of IBS patients \[[@ref51]\]. However, a matched case-control study did not reveal a consistent association between war-related stress (such as shooting a gun or killing a person) and development of functional GI disorders among deployed active-duty soldiers except for an association between "any war stressor" and IBS \[[@ref52]\]. In that study, only diarrhea and vomiting during the deployment period were significantly associated with functional GI disorder development which may suggest a significant role of post-infectious IBS.

Despite the lack of prospective studies to evaluate a direct causal link between life trauma or psychological illness and subsequent IBS, there are emerging data to support interactions between IBS and altered microbiota as well as between behavior and the microbiome. Thus, alterations in gut microbiota may be a confounding factor in the direct evaluation of psychological co-morbidities and functional GI disease, as supported by a study which found differences in the incidence of psychological illness among post-infectious IBS versus non-post-infectious IBS patients \[[@ref53]\]. The relationship between psychological derangements (especially through the hypothalamic-pituitary-adrenal axis) and altered gut microbiota have been evaluated in animal studies in which a surgically-induced state intended to mimic depression was associated with elevated corticotropin-releasing hormone leading to subsequently elevated serotonin levels and hyperactive colonic motility \[[@ref54]\]. Moreover, stress (and the subsequently increased levels of hormonal mediators) may mediate leaky intestinal epithelia and reduced mucosal protection which may be a mechanism by which patients who experience acute gastroenteritis develop subsequent post-infectious IBS \[[@ref55]\].

The opposite effect of an altered microbiome on behavior has been described as well, in which germ-free mice had higher corticosterone levels and a higher stress response which improved with colonization with *Bifidobacterium infantis* \[[@ref56]\]. In a more recent study, specific pathogen-free mice were colonized with microbiota and found to have increased exploratory behavior after administration of oral antibiotics \[[@ref57]\]. While our understanding of this network of factors is only emerging, the complexity of the relationship between IBS and psychological illness is certainly apparent.

Limitations of this study include the small number of eligible studies as well as the variety of methods to evaluate the prevalence and severity of anxiety and depression, which together preclude meaningful statistical analysis. Therefore, this study is intended to merely suggest an association between these GI illnesses and both depression and anxiety. More controlled studies appear warranted. Though the included psychological measures have been validated in evaluating anxiety- and depression-related symptoms, they may not have a primary role in diagnosing mood disorders \[[@ref58]\]. Similar to ongoing discrepancies in the diagnosis of IBS by the various clinical criteria \[[@ref59],[@ref60]\], it also remains uncertain whether results from the multiple psychological rating scales are comparable.

Regardless of the cause of these conditions, the impact of these diseases on quality of life should be considered in a multi-disciplinary approach to therapy. In one prospective IBD cohort, psychological health was found to impact health-related quality of life significantly and independently of disease severity \[[@ref61]\]. The use of existing tools such as the IBD Questionnaire \[[@ref46]\] and IBS Quality of Life \[[@ref62]\] scale should be explored in identifying patients who might benefit from support mechanisms to improve the mental health and quality of life of patients suffering from these chronic illnesses.

In this study, we found that both IBS and UC appear to be associated with increased prevalence and severity of psychological disorders. The pathophysiology of UC appears to be related to immune dysfunction, while the etiology of IBS remains unknown. Therefore, it would be reasonable to continue the pursuit of existing organic mechanistic theories of disease while employing a multi-disciplinary approach to therapy for both conditions.

###### Summary Box

**What is already known:**

A psychosomatic theory has been postulated in irritable bowel syndrome in the absence of other objective etiology and biomarkersMany chronic conditions are associated with psychological disordersUlcerative colitis was associated with psychosomatic theory until the discovery of immune dysregulation

**What the new findings are:**

Both irritable bowel syndrome and ulcerative colitis are associated with psychological disorders versus healthy controlsThe association between irritable bowel syndrome and psychological factors might be attributed to the psychological suffering from chronic and debilitating disease
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